Abivax SA ADS/$ABVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Ticker
$ABVX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
69
ISIN
US00370M1036
Website
Abivax SA ADS Metrics
BasicAdvanced
$528M
-
-$3.44
-
-
Price and volume
Market cap
$528M
52-week high
$8.61
52-week low
$4.77
Average daily volume
316K
Financial strength
Current ratio
1.255
Quick ratio
1.157
Long term debt to equity
-943.538
Total debt to equity
-1,616.535
Interest coverage (TTM)
-12.07%
Profitability
EBITDA (TTM)
-203.858
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,754.30%
Operating margin (TTM)
-1,657.65%
Revenue per employee (TTM)
$175,340
Management effectiveness
Return on equity (TTM)
-196.12%
Valuation
Price to revenue (TTM)
42.204
Price to book
-68.4
Price to tangible book (TTM)
-14.26
Price to free cash flow (TTM)
-2.915
Free cash flow yield (TTM)
-34.30%
Free cash flow per share (TTM)
-283.66%
Growth
Revenue change (TTM)
128.98%
Earnings per share change (TTM)
-11.01%
3-year revenue growth (CAGR)
111.82%
10-year revenue growth (CAGR)
40.87%
3-year earnings per share growth (CAGR)
3.28%
10-year earnings per share growth (CAGR)
13.00%
Bulls say / Bears say
Abivax has successfully completed enrollment for its Phase 3 ABTECT trials evaluating obefazimod in patients with moderately to severely active ulcerative colitis, with top-line results expected in Q3 2025. (abivax.com)
The company reported a strong cash position of €144.2 million as of December 31, 2024, providing a cash runway into Q4 2025, supporting ongoing clinical programs. (abivax.com)
Abivax has initiated an At-The-Market (ATM) program on Nasdaq, allowing the company to raise up to $150 million over the next three years, enhancing financial flexibility for clinical developments. (nasdaq.com)
The termination of Abivax's liquidity contract in October 2024 may impact stock liquidity and investor confidence. (benzinga.com)
The ATM program could lead to potential dilution of up to 39.5% over three years, which may affect existing shareholders' value. (stocktitan.net)
Abivax's focus on a single lead drug candidate, obefazimod, for ulcerative colitis and Crohn's disease, poses a risk if clinical trials do not yield favorable results. (abivax.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Abivax SA ADS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abivax SA ADS stock?
Abivax SA ADS (ABVX) has a market cap of $528M as of July 12, 2025.
What is the P/E ratio for Abivax SA ADS stock?
The price to earnings (P/E) ratio for Abivax SA ADS (ABVX) stock is 0 as of July 12, 2025.
Does Abivax SA ADS stock pay dividends?
No, Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Abivax SA ADS dividend payment date?
Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Abivax SA ADS?
Abivax SA ADS (ABVX) does not currently have a Beta indicator.